158 related articles for article (PubMed ID: 38429698)
41. Breakthrough cancer pain: twenty-five years of study.
Mercadante S; Portenoy RK
Pain; 2016 Dec; 157(12):2657-2663. PubMed ID: 27653423
[TBL] [Abstract][Full Text] [Related]
42. Expert consensus on the management of breakthrough cancer pain in older patients. A Delphi study.
Alarcón MDL; Estévez FV; Cabezón-Gutiérrez L; Padrós MC; Martín-Arroyo JMT; Rebollo MA; Jiménez-López AJ; Sanz-Yagüe A
J Geriatr Oncol; 2019 Jul; 10(4):643-652. PubMed ID: 31036463
[TBL] [Abstract][Full Text] [Related]
43. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
[TBL] [Abstract][Full Text] [Related]
44. Treating breakthrough pain in oncology.
Mercadante S
Expert Rev Anticancer Ther; 2018 May; 18(5):445-449. PubMed ID: 29478355
[TBL] [Abstract][Full Text] [Related]
45. What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion.
; Vellucci R; Fanelli G; Pannuti R; Peruselli C; Adamo S; Alongi G; Amato F; Consoletti L; Lamarca L; Liguori S; Lo Presti C; Maione A; Mameli S; Marinangeli F; Marulli S; Minotti V; Miotti D; Montanari L; Moruzzi G; Palermo S; Parolini M; Poli P; Tirelli W; Valle A; Romualdi P
Drugs; 2016 Mar; 76(3):315-30. PubMed ID: 26755179
[TBL] [Abstract][Full Text] [Related]
46. Effect of a theory-driven educational intervention on the level of knowledge, attitudes, and assessment practices regarding breakthrough cancer pain (BTCP) management among medical nurses in Hong Kong.
Kwok CYL; Chan DNS; So WKW
Eur J Oncol Nurs; 2021 Jun; 52():101945. PubMed ID: 33813183
[TBL] [Abstract][Full Text] [Related]
47. Consensus and controversies in the definition, assessment, treatment and monitoring of BTcP: results of a Delphi study.
Boceta J; De la Torre A; Samper D; Farto M; Sánchez-de la Rosa R
Clin Transl Oncol; 2016 Nov; 18(11):1088-1097. PubMed ID: 26856600
[TBL] [Abstract][Full Text] [Related]
48. How nurses assess breakthrough cancer pain, and the impact of this pain on patients' daily lives--results of a European survey.
Rustøen T; Geerling JI; Pappa T; Rundström C; Weisse I; Williams SC; Zavratnik B; Wengström Y
Eur J Oncol Nurs; 2013 Aug; 17(4):402-7. PubMed ID: 23276599
[TBL] [Abstract][Full Text] [Related]
49. Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients.
Mercadante S; Adile C; Torta R; Varetto A; Fulfaro F; Giarratano A; Casuccio A
Curr Med Res Opin; 2013 Jan; 29(1):93-7. PubMed ID: 23198976
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures.
Pardo J; Mena A; Jiménez E; Aymar N; Ortiz I; Roncero R; Mestre F; Vidal M
Clin Transl Oncol; 2019 Nov; 21(11):1568-1572. PubMed ID: 31093890
[TBL] [Abstract][Full Text] [Related]
51. Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP).
Camps Herrero C; Reina Zoilo JJ; Monge Martín D; Caballero Martínez F; Guillem Porta V; Aranda Aguilar E; Carrato Mena A; Díaz-Rubio García E; García-Foncillas López J; Feijóo Saus M; López López R
Clin Transl Oncol; 2019 Mar; 21(3):380-390. PubMed ID: 30094793
[TBL] [Abstract][Full Text] [Related]
52. Breakthrough pain in patients with abdominal cancer pain.
Mercadante S; Adile C; Giarratano A; Casuccio A
Clin J Pain; 2014 Jun; 30(6):510-4. PubMed ID: 24281289
[TBL] [Abstract][Full Text] [Related]
53. Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care.
Rodríguez AT; Viejo MN; Maradey P; Canal-Sotelo J; Mancilla PG; Rivero SG; Casillas IR; Abián MH; Bermudo CL
Future Oncol; 2022 May; 18(14):1717-1731. PubMed ID: 35137627
[TBL] [Abstract][Full Text] [Related]
54. Practice Patterns in Distinguishing Between Background Pain and Breakthrough Pain During Patient Education: a Korean Physician Survey.
Shin J; Kim DY; Lee J; Choi YS; Hwang IG; Baek SK; Seo MS; Shim JY
J Cancer Educ; 2018 Apr; 33(2):284-292. PubMed ID: 27623849
[TBL] [Abstract][Full Text] [Related]
55. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
Nalamachu SR; Parikh N; Dillaha L; Rauck R
J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
[TBL] [Abstract][Full Text] [Related]
56. Episodic Cancer Pain: Patient Reporting, Prevalence, and Clinicodemographic Associations at Initial Cancer Pain Clinic Assessment.
Reis-Pina P; Acharya A; Barbosa A; Lawlor PG
Pain Res Manag; 2020; 2020():6190862. PubMed ID: 32566062
[TBL] [Abstract][Full Text] [Related]
57. A European survey of oncology nurse breakthrough cancer pain practices.
Rustøen T; Geerling JI; Pappa T; Rundström C; Weisse I; Williams SC; Zavratnik B; Kongsgaard UE; Wengström Y
Eur J Oncol Nurs; 2013 Feb; 17(1):95-100. PubMed ID: 22742829
[TBL] [Abstract][Full Text] [Related]
58. Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study.
Mercadante S; Aielli F; Adile C; Costanzi A; Casuccio A
J Pain Symptom Manage; 2016 Jul; 52(1):27-34. PubMed ID: 27208863
[TBL] [Abstract][Full Text] [Related]
59. European Oncology Nursing Society breakthrough cancer pain guidelines.
Wengström Y; Geerling J; Rustøen T
Eur J Oncol Nurs; 2014 Apr; 18(2):127-31. PubMed ID: 24369817
[TBL] [Abstract][Full Text] [Related]
60. An Observational Research Study to Evaluate the Impact of Breakthrough Cancer Pain on the Daily Lives and Functional Status of Patients.
Twomey F; O'Brien T; O'Reilly M; Bogan C; Fleming J
Ir Med J; 2015 Jun; 108(6):174-6. PubMed ID: 26182800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
